ORIC-114 + amivantamab

ORIC-114 + amivantamab is an investigational combination therapy being evaluated for the first-line treatment of advanced non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations. ORIC-114 is a highly selective, brain penetrant, orally bioavailable, irreversible inhibitor designed to target both EGFR and HER2 with high potency and minimal off-target toxicity. Amivantamab (marketed as Rybrevant) is a fully human bispecific monoclonal antibody that targets both EGFR and MET receptors. The combination aims to address therapeutic resistance in NSCLC patients, particularly those with brain metastases or who have progressed on prior therapies. A Phase 1b trial sponsored by ORIC Pharmaceuticals in collaboration with Janssen Research & Development (a Johnson & Johnson company) will assess safety, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of this regimen[1][3][6][7].